Skip to main
IMAB
IMAB logo

I-Mab (IMAB) Stock Forecast & Price Target

I-Mab (IMAB) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

I-MAB's stock outlook is supported by its advanced drug pipeline, notably the promising development of Givastomig, which demonstrates a favorable safety profile and higher binding affinity, indicating enhanced efficacy and potential for expanded market opportunities. The anticipated Hong Kong IPO is expected to diversify the shareholder base and help align I-MAB's valuation with that of its Asia-listed peers, potentially enhancing investor interest and market perception. Moreover, the appointment of a new CFO with substantial capital markets experience bolsters I-MAB's financial strategy and enhances investor communication ahead of significant clinical milestones projected for 2026.

Bears say

I-MAB's stock experienced a decline of approximately 12% following recent announcements, indicating potential investor concerns and profit-taking activities. The company's decision to implement a hub-and-spoke model, alongside existing capacity constraints, raises questions about its operational efficiency and future growth potential. These fundamental challenges within I-MAB's strategic focus contribute to a negative outlook on its financial prospects.

I-Mab (IMAB) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of I-Mab and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About I-Mab (IMAB) Forecast

Analysts have given I-Mab (IMAB) a Strong Buy based on their latest research and market trends.

According to 4 analysts, I-Mab (IMAB) has a Strong Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

I-Mab (IMAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.